chevron_leftBack
As of 18 June 2026, Tenax Therapeutics, Inc. has a market cap of $314.85M USD, ranking #18341 globally and #3059 in the United States.
It ranks #1659 in the Healthcare sector, and #602 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$314.85MUSD
Enterprise Value
$656.08MUSD
Net Income (TTM)
-$52.6MUSD
PB Ratio
6.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher Giordano
open_in_new
Employees
16
Founded
1967
Website
tenaxthera.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -12% | -8.2% | -14% | -8.8% | 77% | 118% |
News
Loading...
TENX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TENX
Tenax Therapeutics Inc
ISIN: US88032L6056
Shares Out.:
Shares Outstanding:
26.525M1
Shares Float:
24.068M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
12.78 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
242K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
174K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
114K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
87K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
47K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
37K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.45B
102K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$287.52B
91K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.59B
87K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.51B
58K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$109.92B
35K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$107.97B
34K%
80.96B GBP
|
14.6
|
chevron_leftBack